{"resourceType": "Evidence", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"], "versionId": "50", "lastUpdated": "2024-08-21T11:36:45.318Z"}, "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "236967", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "313960"}, {"type": {"text": "picoId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "85798"}, {"type": {"text": "sectionId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "73215"}], "name": "End_stage_kidney_diseaseComparator_Evidence_from_MAGICapp_313960", "title": "MAGIC-derived Evidence: End-stage kidney disease Comparator Evidence", "status": "active", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ComparatorOnlyEvidence", "display": "ComparatorOnlyEvidence"}]}}], "relatedArtifact": [{"type": "part-of", "resourceReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}], "note": [{"text": "Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR > 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/)."}], "variableDefinition": [{"description": "Adults with type 2 diabetes -- GLP-1 RA", "variableRole": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/variable-role", "code": "population", "display": "population"}], "text": "Use extension:variableRoleCode instead."}, "observed": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-comparator-group-MAGIC-5288-j1Wqrn-comparator-85394-C-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Group/236948"}, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code", "valueCode": "population"}], "note": [{"text": "population"}]}, {"description": "End-stage kidney disease", "variableRole": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/variable-role", "code": "measuredVariable", "display": "measured variable"}], "text": "Use extension:variableRoleCode instead."}, "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-313960", "assigner": {"display": "Computable Publishing LLC"}}, "display": "End-stage kidney disease", "reference": "EvidenceVariable/236965"}, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code", "valueCode": "outcome"}], "note": [{"text": "outcome"}]}], "synthesisType": {"text": "NOTSET"}, "studyDesign": [{"text": "NO_STUDY"}], "statistic": [{"description": "Risk 11.9%", "statisticType": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/statistic-type", "version": "5.0.0-cibuild", "code": "C44256", "display": "Proportion"}]}, "quantity": {"value": 0.119}}], "url": "https://fevir.net/resources/Evidence/236967", "id": "236967", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}]}